Resumen de: CN116196404A

本公开涉及一种基于激活的抗原提呈细胞膜组分的核酸递送粒子、核酸递送系统及其制备方法及应用，使用负载全细胞组分的纳米粒子或微米粒子激活抗原提呈细胞后将抗原提呈细胞的膜组分负载于已经内部负载mRNA的核酸递送前体粒子后，得到本公开中的核酸递送粒子。本公开提供的核酸递送粒子克服了mRNA递送过程中面临的无法在4摄氏度度或室温下长期储存、递送效率低等问题，能够高效的将mRNA递送到抗原提呈细胞并激活癌细胞特异性免疫反应，可用于癌症等疾病的预防和治疗。

Resumen de: CN116196293A

本发明公开了一种用于治疗溃疡性结肠炎的肠溶性木质素细菌包埋颗粒及其制备。本发明利用静电相互作用的原理，使用阴离子型木质素包埋细菌，在中性或弱碱性条件下，细菌表面带有负电荷，通过静电相互作用使细菌表面吸附一层Ca2+，然后Ca2+再吸附阴离子型木质素，在细菌表面形成一层纳米涂层，实现对细菌的包埋。本发明所述肠溶性木质素细菌包埋颗粒制备过程简单，不但提高了细菌在模拟胃液中的活菌数，在模拟肠液中顺利释放，而且木质素与被包埋的细菌可以发挥协同治疗作用，有效治疗DSS诱导的小鼠结肠炎，增长患病小鼠的结肠长度，为细菌口服新剂型的开发提供新思路，并且扩大木质素的高值化应用范围，促进生物质资源的开发与应用。

Resumen de: CN116196291A

一种RGD修饰的雷公藤红素白蛋白纳米粒及其制备方法和应用，属于生物医药技术领域。一种雷公藤红素白蛋白纳米粒，是白蛋白包载雷公藤红素形成纳米粒。RGD修饰的雷公藤红素白蛋白纳米粒是精氨酸‑甘氨酸‑天冬氨酸环状三肽(RGD环肽)修饰于雷公藤红素白蛋白纳米粒表面而形成。RGD修饰的雷公藤红素白蛋白纳米粒可以特异性靶向并穿透中性粒细胞，诱导中性粒细胞凋亡，在治疗类风湿性关节炎和炎症疾病方面具有良好的效果。

Resumen de: CN116199646A

本发明涉及一种基于Tris的可电离脂质及其制备方法与应用，所述脂质含有包含含氮杂环环的头部基团，以三羟甲基氨基甲烷(Tris)为核心的连接部和碳链尾；所制备的脂质纳米颗粒配方包含可电离脂质、胆固醇、PEG脂质、辅助脂质以及核酸药物，可将核酸安全高效地转染入细胞中，在纳米核酸疫苗、核酸药物制剂等基因治疗领域具有广阔的应用前景。

Resumen de: CN116196292A

本发明涉及一种靶向肽修饰的聚酰胺‑胺树状大分子复合纳米材料及其制备方法，所述复合纳米材料为表面修饰mPEG或者PEG‑LyP‑1、内部包裹金属纳米颗粒和肿瘤血管破坏剂的第五代聚酰胺‑胺(PAMAM)树状大分子(G5)。本发明的复合纳米材料具有良好的单分散性、胶体稳定性和光热成像功能，可将光热治疗和免疫治疗两种治疗模式集中在一个纳米平台上用于肿瘤的治疗和抗转移，具有潜在的临床应用价值。

Resumen de: CN116196442A

本发明涉及诊断成像领域，尤其涉及一种口服式淋巴及免疫器官高效导诊剂及其制备方法和应用，所述导诊剂，包括食源功能性纳米晶体；以及包覆在食源功能性纳米晶体外部并与之结合的荧光染料。本发明创新性地将然食源功能性纳米晶体（iFNPs）与荧光染料进行结合，能够使得生物探针在肠道派氏淋巴组织中富集效果提高了10倍以上，在淋巴结富集效果增强至少7倍以上，在免疫器官如脾脏中的靶向性至少增强了150%，同时基于天然纳米晶体包覆的策略在免疫器官中具有成功的应用分布，极大地提升了医疗成像分辨率，有利于进一步发展高精度医疗导诊，并且还可以有效降低和控制生物探针毒性，降低了使用风险，拓展应用场景。

Resumen de: WO2022032140A2

The disclosure provides a novel method for treating genetic disorders where a peptide sequence targets proteins produced via gene therapy into exosomes. These protein-loaded exosomes can enter into non-transduced cells and correct pathology. Also, gene therapy compositions, protein replacement therapy composition, pharmaceutical compositions, methods of treatment, and uses of the gene therapy compositions and the recombinant proteins are also disclosed. The method can also be used to improve in vitro recombinant protein yield.

Resumen de: WO2022009118A1

The present invention relates to a technological platform for the delivery of lipophilic active ingredients.

Resumen de: WO2021255492A1

The present invention provides a cancer drug for use in the treatment of cancer in which caffeic acid phenethyl ester (CAPE) is encapsulated in poly [lactic-co-glycolic acid] (PLGA) to increase its solubility in aqueous media. Angiopep-2 is used as a specific ligand to increase biological activity. In an embodiment of the invention, PLGA is preferably in the form of nanoparticles, thereby ensuring better solubility.

Resumen de: CN116199666A

本发明公开了一种两亲性化合物及其药物组合物，该化合物具有式I的结构，其中的环状二硫化物可以与细胞外表面硫醇之间发生动态共价二硫键交换介导其进入细胞质；甜菜碱具有阳离子和阴离子电荷群，通过静电相互作用形成较强的水合层，带有甜菜碱结构的两亲性化合物使得环状二硫化物易于暴露于纳米载体表面并达到抗蛋白吸附的作用，延长血液循环时间。修饰有该功能化两亲性化合物的纳米载体可以通过非胞吞途径高效稳定的将药物直接递送到胞质。

Resumen de: US2023165804A1

The invention relates to solid lipid nanoparticle for intracellular release of active substances, can be used in the pharmaceutical industry, in the medicine, cosmetics, as well as for food supplements. Solid lipid nanoparticle has spherical shape with a diameter of 15 - 100 nm, the lipid is a solid lipid selected from natural plant wax or its synthetic analogue, as the surface acting agent is used TMDSC. The particles of solid lipid nanoparticle is characterized with high melting point, high lipophilicity and low (or lack) of in-vitro dissolution profile. The system is lipase-resistant and is capable to freely penetrate through cell membranes into cells where to release the active substance(s) due to an intracellular digestion with controllable depo-effect. In a second aspect, the invention relates to a method of production of the solid lipid nanoparticle. The preferred technology for production of the compositions is a Phase Inversion Temperature method.

Resumen de: US2023165798A1

The invention relates to a method of treating parasitic etiologies of ophthalmic diseases in the eyelash, eyelid, or cutaneous tissue surrounding the eyelash or eyelid by topically applying to the eyelash, eyelid, or cutaneous tissue surrounding the eyelash or eyelid a formulation of antiparasitic agents such as macrocyclic lactone parasiticides, comprising of suspended particles of ivermectin and polymer solid dispersion in a suitable pharmaceutically carrier. The formulation may include particles of ivermectin and a polymer having a D90 particle size below about 10 microns preferably between about 800 nm and about 4 microns. The polymer may be an extended release polymer. The formulation may further include mineral oil and an anhydrous gel. The formulation may have a viscosity between 30,000 cP and about 100,000 cP preferably between about 40,000 cP and about 90,000 cP.

Resumen de: US2023165797A1

Cerium oxide nanoparticles (CNPs) have been proven to exhibit antioxidant properties attributed to its surface oxidation states (Ce4+ to Ce3+ and vice versa) mediated at the oxygen vacancies on the surface of CNPs. Different anions in precursor cerium salts were used to prepare CNPs resulting in disclosed CNPs with varying physicochemical properties such as dispersion stability, hydrodynamic size, and the signature surface chemistry. The antioxidant catalytic activity and oxidation potentials of different CNPs have been significantly altered with the change of anions in the precursor salts. For one, CNPs prepared using precursor salts containing NO3− and Cl− ions exhibited increased antioxidant activity than previously thought possible. The change in oxidation potentials of CNPs with the change in concentration of the nitrate and chloride ions indicates the disclosed CNP's have different surface chemistry and antioxidant properties. These compositions and methods of their synthesis are disclosed.

Resumen de: US2023165783A1

This disclosure relates generally to a sunscreen composition containing visibly transparent biocompatible ultraviolet blocking polymer nanoparticles. The sunscreen composition comprising polydimethylsiloxane (PDMS) nanoparticles, at least one flavoring agent, at least one coloring agent, at least one stabilizer, and at least one preservative, in a defined form, wherein size of the PDMS nanoparticles ranging from 200 to 1200 nm. The size of the PDMS nanoparticles ranging from 200 to 500 nm for air medium and from 800 to 1200 nm for water medium. The PDMS nanoparticles comprise a PDMS polymer having terminal functional group selected from alkyl, alkoxy, vinyl, hydroxyl, or a combination thereof. The sunscreen composition is available in the defined form selected from a group consisting of a skin cream, a skin lotion, a powder, a gel, and a sprayable liquid.

Resumen de: US2023167437A1

The present application provides guide RNAs and genome-editing complexes or nanoparticles that are useful for specifically targeting a mutated KRAS. Exemplary genome-editing complexes or nanoparticles comprise cell-penetrating peptides, and optionally a DNA nuclease (such as Cas9) or a polynucleotide encoding the DNA nuclease.

Resumen de: US2023167181A1

The present disclosure provides pharmaceutical compositions comprising a thermally conductive excipient which may be used to improve the heat transfer within the pharmaceutical compositions in a high energy mixing process. The resultant pharmaceutical compositions may be amorphous in nature and improve the processability of thermally labile or shear sensitive active agents.

Resumen de: US2023167149A1

CD33 ligands which are useful for the synthesis of CD33 ligand-bearing carriers, wherein said CD33 ligand bearing carriers are directly or indirectly linked to or associated with at least one anti-cancer agent, are described herein. Uses of said CD33 ligand-bearing carriers for treating and/or preventing a disease, disorder, or condition such as acute myeloid leukemia (AML) are also described. The ligands have formula (I) below.

Resumen de: US2023166231A1

Compositions and methods are provided for making hyper compliant polymer particles by inverse emulsification and having a predetermined mechanical compliance and a predetermined size with a monodisperse diameter. Compositions and methods are provided for use of hyper compliant polymer particles in drug delivery, assay, particle image velocimetry, ceramics, cosmetics, deconvolution, electronic paper, insulation, personal care, standards, retroreflective paint and paint applications, thickening agents, regenerative medicine, device calibration, micro-carriers and force indicators.

Resumen de: AU2021385841A1

Ligand-bound gold clusters and compositions comprising the ligand-bound gold clusters are used for treating cerebral stroke and manufacturing a medicament for treatment of cerebral stroke. Methods for treating cerebral stroke.

Resumen de: WO2023097310A1

The present disclosure provides microcapsules comprising a silk fibroin polypeptide and one or more active payload, materials, and formulations comprising the microcapsules of the disclosure. Also provided are methods of preparing and methods of using the microcapsules of the disclosure.

Resumen de: WO2023097232A1

The present invention provides peptide nucleic acids, and nanoparticles comprising the same. The invention also provides methods of treating diseases, reducing tumor growth, increasing sensitivity to a chemotherapy, prolonging survival time, and increasing apoptosis of tumor cells in a subject in need thereof.

Resumen de: WO2023097265A1

The present invention provides both QuilA-loaded chitosan (QAC)-encapsulated NA vaccine compositions and viral vaccine compositions that encode an Infectious Bronchitis Virus (IB V) spike (S) protein, an IBV nucleocapsid (N) protein, or both the S protein and the N protein. Additionally, the present invention provides methods in which the disclosed vaccines are administered to a subject to induce an immune response against IBV or to vaccinate the subject against IBV.

Resumen de: WO2023097260A1

The present disclosure relates to a process for the preparation of tolerizing immune modifying nanoparticles encapsulating peanut proteins, compositions comprising the particles and use thereof for the treatment of peanut allergy.

Resumen de: WO2023097027A1

Described herein are high-boiling-point-based nanoparticles that release drugs specifically at the focus of ultrasound. The specific conjunction of the high-boiling-point-based nanoparticle formulation with low-frequency ultrasound can be used to deliver therapeutics in a safe and effective manner. The effectiveness and safety of the release is validated in vitro and in non-human primates.